NBTX on Nasdaq

Nanobiotix S.A.

Our legal and commercial name is Nanobiotix S.A. We were incorporated as a société anonyme under the laws of the French Republic on March 4, 2003 for a period of 99 years.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

32.6MRevenue, fiscal 20252
-24.0MNet income, fiscal 20252

Compare with Inventiva S.A., Ascendis Pharma A/S or Evotec SE, or pick any stock.

  • TickerNBTX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersI01
  • Incorporated inFrance3
  • Business address60 Rue De Wattignies, Paris, I0 750123
  • Filer categoryAccelerated filer3

See how the biggest companies compare on our leaderboards

Our legal and commercial name is Nanobiotix S.A. We were incorporated as a société anonyme under the laws of the French Republic on March 4, 2003 for a period of 99 years. We are registered at the Paris Registre du Commerce et des Sociétés under the number 447 521 600. Our principal executive offices are located at 60, rue de Wattignies, 75012 Paris, France, and our telephone number is +33 1 40 26 04 70. Our agent for service of process in the United States is our U.S. subsidiary, Nanobiotix Corporation, located at 245 Main Street, Cambridge, Massachusetts 02142. Our ordinary shares began trading on the regulated market of Euronext in Paris in October 2012. Our ADSs began trading on the Nasdaq Global Select Market on December 11, 2020.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

-33.2%Operating margin2
-73.5%Net margin2
-553.2%Revenue growth, 20252
-34.0M EURFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development39¢23.1M EUR
  • Selling, general and admin35¢20.4M EUR
  • Interest26¢15.2M EUR
  • Income tax0¢3.0K EUR

Out of 32.6M EUR in revenue.2 The company lost money this year.

Financial statements

Revenue56789232.6M EUR in 2025+837% since 2018
-20.0M EUR020.0M EUR40.0M EUR2018: 3.5M EUR3.5M EUR20182019: 2.5M EUR2.5M EUR2019−27%2020: 2.5M EUR2.5M EUR2020−1%2021: 2.6M EUR2.6M EUR2021+5%2022: 4.8M EUR4.8M EUR2022+80%2023: 36.2M EUR36.2M EUR2023+658%2024: -7.2M EUR-7.2M EUR20242025: 32.6M EUR32.6M EUR2025
Operating income567892-10.8M EUR in 2025−64% since 2018
-80.0M EUR-60.0M EUR-40.0M EUR-20.0M EUR02018: -30.1M EUR-30.1M EUR20182019: -46.8M EUR-46.8M EUR2019+56%2020: -36.4M EUR-36.4M EUR2020−22%2021: -52.6M EUR-52.6M EUR2021+44%2022: -46.7M EUR-46.7M EUR2022−11%2023: -26.8M EUR-26.8M EUR2023−43%2024: -68.4M EUR-68.4M EUR2024+155%2025: -10.8M EUR-10.8M EUR2025−84%
Net income56782-24.0M EUR in 2025−21% since 2018
-80.0M EUR-60.0M EUR-40.0M EUR-20.0M EUR02018: -30.3M EUR-30.3M EUR20182019: -50.9M EUR-50.9M EUR2019+68%2020: -33.6M EUR-33.6M EUR2020−34%2021: -47.0M EUR-47.0M EUR2021+40%2022: -57.0M EUR-57.0M EUR2022+21%2023: -39.7M EUR-39.7M EUR2023−30%2024: -68.1M EUR-68.1M EUR2024+72%2025: -24.0M EUR-24.0M EUR2025−65%

Every line of the income statement as filed: the last 4 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-312022-12-31
Revenues29.6M EUR-11.6M EUR30.1M EUR
Other income3.0M EUR4.4M EUR6.2M EUR
Total revenues and other income32.6M EUR-7.2M EUR36.2M EUR
Research and development expenses-23.1M EUR-40.5M EUR-38.4M EUR
Selling, general and administrative expenses-20.4M EUR-20.5M EUR-22.0M EUR
Other operating income and expenses64.0K EUR-134.0K EUR-2.5M EUR
Total operating expenses-43.4M EUR-61.2M EUR-63.0M EUR
Operating income (loss)-10.8M EUR-68.4M EUR-26.8M EUR
Financial income2.1M EUR7.8M EUR2.0M EUR
Financial expenses-15.2M EUR-7.5M EUR-14.8M EUR
Net financial income (loss)-13.1M EUR361.0K EUR-12.8M EUR
Income tax-3.0K EUR-101.0K EUR-120.0K EUR
Net loss for the period-24.0M EUR-68.1M EUR-39.7M EUR-57.0M EUR
Basic loss per share (in euro per share)-0.50 EUR-1.44 EUR-1.08 EUR
Diluted loss per share (in euro per share)-0.50 EUR-1.44 EUR-1.08 EUR

Compare Nanobiotix S.A. with another company

Filings

240 filings to the SEC since October 2021: 5 annual reports, 14 large holders, 221 other. The latest 20:

  1. Oct 1, 20266-K EDGAR
  2. Sep 24, 20266-K EDGAR
  3. Sep 24, 20266-K EDGAR
  4. Sep 22, 20266-K EDGAR
  5. Sep 14, 20266-K EDGAR
  6. Sep 9, 20266-K EDGAR
  7. Aug 25, 20266-K EDGAR
  8. Aug 13, 2026SCHEDULE 13G/A EDGAR
  9. Jul 31, 20266-K EDGAR
  10. Jul 29, 2026SCHEDULE 13G/A EDGAR
  11. Jun 8, 2026S-8 EDGAR
  12. Jun 5, 20266-K EDGAR
  13. Jun 2, 20266-K EDGAR
  14. Jun 2, 20266-K EDGAR
  15. May 26, 20266-K EDGAR
  16. May 26, 20266-K EDGAR
  17. May 22, 20266-K EDGAR
  18. May 22, 2026FWP EDGAR
  19. May 22, 2026424B5 EDGAR
  20. May 21, 20266-K EDGAR

The 240 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Johnson & Johnson5,623,816$212.0M26.5%No change
Morgan Stanley49,789$1.9M0.0%+13,515
Jane Street Group, LLC32,180$1.2M0.0%New
XTX Topco Ltd15,855$597.7K0.0%New
Optiver Holding B.V.13,631$513.9K0.0%+130
Marshall Wace, Llp10,044$378.7K0.0%+805
Citadel Advisors LLC6,042$227.8K0.0%New
Bnp Paribas Financial Markets4,044$152.5K0.0%+485
UBS Group AG2,577$97.2K0.0%−2,980
Royal Bank Of Canada2,189$83.0K0.0%+364
Jpmorgan Chase & Co1,706$61.3K0.0%New
Rhumbline Advisers1,502$56.6K0.0%−779
GAMMA Investing LLC985$37.1K0.0%+157
Osaic Holdings, Inc.500$18.9K0.0%No change
Wells Fargo & Company/mn200$7.5K0.0%No change
Stone House Investment Management, LLC76$2.9K0.0%New
Federation des caisses Desjardins du Quebec56$2.1K0.0%New
Hrt Financial LP27,332$1.0K0.0%New
National Bank Of Canada /fi/13$4820.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14